Nutraceutical Shows Promise for Reduction of Covid-19 Spike Protein

Nutraceutical Shows Promise for Reduction of Covid-19 Spike Protein

By: Dylan Sikes – AllPennyStocks.com News

Monday, January 3, 2022

The war against the coronavirus continues and this company just announced positive results of a pilot clinical trial showing decreased production of cytokine.

Therapeutic Solutions International (OTC: TSOI) focuses on immune modulation. A recent study involving the firm’s QuadraMune has showed a significantly decreased production of the inflammatory cytokine interleukin-6, according to the company’s press release.

QuadraMune suppresses inflammatory pathways associated with COVID-19 mortality, while at the same time inhibits immune suppressive enzymes. The firm is exploring immune strategies as new variants emerge.  

Shares were rallying, up 17 percent in afternoon trade. 


Copyright © 2021 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Dual Listed Biotech Firm Achieves Sale of Animal Health Interest, Sending Shares Higher
Could This Stock Be The Next Big Mover In The Short-Term Rental Market?
Micro Cap Massively Bid Up Before Opening Bell
Most Popular
FREE Newsletter
AllPennyStocks.com Favorites


Back to Top